Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 2/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
| ▸ | TUBB | P07437 | 1/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naproxen SCHEMBL5184488 | 0.88 | AKR1C3 (0.66) | AKR1C2PTGS1AKR1C3CYP1A2 | |
| SCHEMBL2169014 | 0.87 | PTGS1 (0.47) | AKR1C2PTGS1AKR1C3HSD17B10KDM4E | |
| SCHEMBL9504259 | 0.87 | KDM4E (0.53) | AKR1C2PTGS1AKR1C3KDM4EALDH1A1 | |
| SCHEMBL2168667 | 0.86 | AKR1C3 (0.48) | AKR1C2PTGS1AKR1C3HSD17B10KDM4E | |
| SCHEMBL11466749 | 0.85 | PTGS1 (0.59) | AKR1C2PTGS1AKR1C3HSD17B10KDM4E | |
| SCHEMBL11600360 | 0.84 | PTGS1 (0.57) | AKR1C2PTGS1AKR1C3HSD17B10KDM4E | |
| SCHEMBL11783844 | 0.84 | AKR1C3 (0.57) | AKR1C2PTGS1AKR1C3HSD17B10KDM4E | |
| SCHEMBL11780198 | 0.84 | PTGS1 (0.57) | AKR1C2PTGS1AKR1C3HSD17B10KDM4E | |
| SCHEMBL11781091 | 0.84 | AKR1C3 (0.57) | AKR1C2PTGS1AKR1C3HSD17B10KDM4E | |
| SCHEMBL11778406 | 0.84 | PTGS1 (0.57) | AKR1C2PTGS1AKR1C3HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10105455-B2 | Fluorocoxib A loading into ROS-responsive nanoparticles | VANDERBILT UNIVERSITY (US) | 2018-10-23 | — | — | US | claimed |
| US-20170007723-A1 | FLUOROCOXIB A LOADING INTO ROS-RESPONSIVE NANOPARTICLES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-01-12 | — | — | US | claimed |
| EP-2040699-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | Vanderbilt University Medical Center (US) | 2009-04-01 | — | — | EP | claimed |
| WO-2007149456-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2007-12-27 | — | — | WO | claimed |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | VANDERBILT UNIVERSITY (US) | 2007-12-20 | — | — | US | claimed |
| EP-1148783-B1 | CONVERTING COX INHIBITION COMPOUNDS THAT ARE NOT COX-2 SELECTIVE INHIBITORS TO DERIVATIVES THAT ARE COX-2 SELECTIVE INHIBITORS | UNIV VANDERBILT (US) | 2006-06-07 | — | — | EP | claimed |
| EP-1638612-A2 | COX-2-TARGETED IMAGING AGENTS | Vanderbilt University (US) | 2006-03-29 | — | — | EP | claimed |
| WO-2005002293-A2 | COX-2-TARGETED IMAGING AGENTS | VANDERBILT UNIVERSITY (US) | 2005-01-06 | — | — | WO | claimed |
| US-20050002859-A1 | COX-2-targeted imaging agents | VANDERBILT UNIVERSITY (US) | 2005-01-06 | — | — | US | claimed |
| US-6762182-B1 | FORMING ESTER OR SECONDARY AMIDE DERIVATIVE OF SUCH AS INDOMETHACIN | VANDERBILT UNIVERSITY | 2004-07-13 | — | — | US | claimed |
| EP-1148783-A4 | CONVERTING COX INHIBITION COMPOUNDS THAT ARE NOT COX-2 SELECTIVE INHIBITORS TO DERIVATIVES THAT ARE COX-2 SELECTIVE INHIBITORS | UNIV VANDERBILT (US) | 2003-05-21 | — | — | EP | claimed |
| US-6399647-B2 | ANTICANCER AGENTS; CYCLOOXYGENASE INHIBITOR | VANDERBILT UNIVERSITY | 2002-06-04 | — | — | US | claimed |
| EP-1148783-A1 | CONVERTING COX INHIBITION COMPOUNDS THAT ARE NOT COX-2 SELECTIVE INHIBITORS TO DERIVATIVES THAT ARE COX-2 SELECTIVE INHIBITORS | Vanderbilt University (US) | 2001-10-31 | — | — | EP | claimed |
| US-20010034361-A1 | Amide derivatives for antiangiogenic and/or antitumorigenic use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-10-25 | — | — | US | claimed |
| EP-1146788-A1 | AMIDE DERIVATIVES FOR ANTIANGIOGENIC AND/OR ANTITUMORIGENIC USE | Vanderbilt University (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2000040088-A1 | AMIDE DERIVATIVES FOR ANTIANGIOGENIC AND/OR ANTITUMORIGENIC USE | VANDERBILT UNIVERSITY (US) | 2000-07-13 | — | — | WO | claimed |
| WO-2000040087-A1 | CONVERTING COX INHIBITION COMPOUNDS THAT ARE NOT COX-2 SELECTIVE INHIBITORS TO DERIVATIVES THAT ARE COX-2 SELECTIVE INHIBITORS | VANDERBILT UNIVERSITY (US) | 2000-07-13 | — | — | WO | claimed |
| EP-0805793-A1 | PREPARATION OF OPTICALLY ACTIVE ALIPHATIC CARBOXYLIC ACIDS | ALBEMARLE CORPORATION (US) | 1997-11-12 | — | — | EP | claimed |
| WO-1997013519-A1 | ESTERS OF CYCLOOXYGENASE INHIBITORS AND TERPENE DERIVATIVES AS PHARMACEUTICAL PRODUCTS | RUSSINSKY LIMITED (IE) | 1997-04-17 | — | — | WO | claimed |
| WO-1996022959-A1 | PREPARATION OF OPTICALLY ACTIVE ALIPHATIC CARBOXYLIC ACIDS | ALBEMARLE CORPORATION (US) | 1996-08-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034361-A1 | Amide derivatives for antiangiogenic and/or antitumorigenic use | PTGS1, PTGS2, HPGDS | AKR1C2 1581/4885PTGS1 1/4885AKR1C3 1538/4885 |
| US-20050002859-A1 | COX-2-targeted imaging agents | PTGS2, PTGES2, PTGER2 | AKR1C2 2409/4885PTGS1 5/4885AKR1C3 1610/4885 |
| US-20170007723-A1 | FLUOROCOXIB A LOADING INTO ROS-RESPONSIVE NANOPARTICLES | ROS1, CYBB, NOXO1 | AKR1C2 1036/4885PTGS1 16/4885AKR1C3 1125/4885 |
| US-10105455-B2 | Fluorocoxib A loading into ROS-responsive nanoparticles | ROS1, CYBB, NOXO1 | AKR1C2 1036/4885PTGS1 16/4885AKR1C3 1125/4885 |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | PTGES2, PTGS2, PTGER2 | AKR1C2 1702/4885PTGS1 4/4885AKR1C3 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.